Intravenous ibandronate: In the treatment of osteoporosis

Drugs

Volumn 66, Issue 12, 2006, Pages 1593-1601

  Croom, Katherine F ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IBANDRONIC ACID; PLACEBO;

ABDOMINAL PAIN; ARTHRALGIA; BONE DENSITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGUS DISEASE; FATIGUE; FLU LIKE SYNDROME; GASTRITIS; HUMAN; LUMBAR SPINE; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PHARMACODYNAMICS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; SPINE FRACTURE; TREATMENT INDICATION;

ANIMALS; AREA UNDER CURVE; BONE AND BONES; BONE DENSITY; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE DISTRIBUTION;

EID: 33748525876     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666120-00005     Document Type: Review

References (22)

1. Scottish Intercollegiate Guidelines Network. Management of osteoporosis: a national clinical guideline. June 2003 (updated Apr 2004) [online]. Available from URL: http://www.sign.ac.uk [Accessed 2006 Jun 12]
2. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006; 13 (3): 340-67
3. Cranney A. Treatment of postmenopausal osteoporosis: choice of treatment depends on efficacy, individual risk profile, and side effects. BMJ 2003; 327: 355-6
4. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19 (8): 1241-9
5. Roche Products Limited. Bonviva 150mg film-coated tablets: summary of product characteristics (EC) [online]. Available from URL: http://www.emc. medicines.org.uk [Accessed 2006 Jun 12]
6. Roche Products Limited. Bonviva 3mg/3ml solution for injection in pre-filled syringe: summary of product characteristics (EC) [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2006 Apr 26]
7. Chapurlat RD. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Treat Endocrinol 2005; 4 (2): 115-25
8. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004 Jun; 15 (6): 423-33
9. Thiebaud D, Burckhardt P, Kriegbaum H, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997 Oct; 103 (4): 298-307
10. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004 May; 34 (5): 881-9
11. Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003 Oct; 62 (10): 969-75
12. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004 Sep; 44 (9): 951-65
13. Delmas PD, Adami S, Strugala CSJA, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis. Arthritis Rheum 2006; 54 (6): 1838-46
14. Recker R, Stakkestad JA, Chesnut CH, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004 May; 34 (5): 890-9
15. Emkey R, Zaidi M, Lewiecki EM, et al. Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study [abstract no. L8 plus poster]. 69th Annual Scientific Meeting of the American College of Rheumatology and the 40th Annual Meeting of the Association of Rheumatology Health Professionals: Late Breakers; 2005 Nov 12-17; San Diego (CA)
16. Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004 Oct; 15 (10): 792-8
17. Data on file. F. Hoffman-La Roche Ltd, Basel, 2006
18. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000 Jan; 85 (1): 231-6
19. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002 Apr; 87 (4): 1586-92
20. Ringe JD, Dorst A, Faber H, et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003 Oct; 14 (10): 801-7
21. Ringe JD, Dorst A, Faber H. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int 2005 Dec; 16 (12): 2063-8
22. Roche Laboratories Inc. Boniva. (ibandronate sodium) injection: package insert (US). [online]. Available from URL: http://www.rocheusa.com [Accessed 2006 Jul 25]